Orphan Drugs 2019
Sponsors & Exhibitors
SKC consulting is the leading and most reputable strategy consultancy in the German health care sector. The company was founded in 2005 as as pin-off of the Boston Consulting Group and the Hannover Medical School (MHH) with a focus on companies, organizations and institutions in the German and international health care markets.Our managing directors and colleagues are experienced and reliable advisors to pharmaceutical, medical and biotechnological companies as well as health insurances. With our profound knowledge of the German and the European health care systems, we support our clients in meeting their strategic challenges,especially in Market Access, Pricing and Reimbursement and Strategic Communication.We at SKC think that every activity in the healthcare industry should focus on the improvement of the patient’s situation. We are convinced that the best solution for a health care problem can only be found in a competitive landscape, shaped by innovation and empowered by trust. We believe a better, more effective, efficient and fair healthcare system is possible due to digital technologies, interdisciplinary networks and highest professional standards. Visit skc-consulting.de
Eiger is a late‐stage biopharmaceutical companyfocused on the accelerated development andcommercialization of a pipeline of targeted, first‐in‐class therapies for rare and ultra‐rarediseases. The company’s lead program is inPhase 3, developing lonafarnib, a first‐in‐classprenylation inhibitor for the treatment ofHepatitis Delta Virus (HDV) infection. Thecompany is also preparing an NDA with plans tofile in 2019 for lonafarnib in the treatment ofHutchinson‐Gilford Progeria Syndrome (HGPS orProgeria) and Progeroid Laminopathies.For additional information about Eiger, please visit www.eigerbio.com
Invitae Corporation (NYSE: NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices. Please visit invitae.com
Durbin is one of the leading providers of comparator sourcing and managed access programs to pharmaceutical and biotech companies around the world. In its 55th year of business, Durbin is pleased to look back on a history of sourcing pharmaceuticals for physicians and patients around the world and even in 3rd world countries, providing urgent and cost effective supply of pharmaceuticals to global charity and relief organizations and of course its pharmaceutical services division who source and distribute comparator drugs for clinical trials and run managed access programs that provide access to needed pharmaceuticals in non- approved markets. Durbin’s distribution network includes regular shipments to over 180 countries globally. Their managed access programs include orphan, gene, and controlled products.
Durbin has full service offices in the United Kingdom, European Union and United States. http://www.durbinglobal.com/
Pulse Infoframe Inc (Pulse) believes thatcollaboration cures disease and Pulse enablessuch collaboration. A new style of healthcareinformatics company, Pulsebuilds and supports global, healthcareecosystems. It’s solution, healthie™, empowersconsortia of pharmaceutical and medical devicecompanies, researchers, clinicians, advocacygroups and patients, by aggregating informationfrom a variety of sources and then, delivering keyhealthcare insights – real time -- derived fromthese data. For patients with rare diseases, Pulse’sglobal coverage is critical. Already great strideshave been made in characterizing rare diseasesusing Pulse’s global and national registries. Theseinsights help professionals to advance medicalresearch, focus clinical trial recruitment, assistadvocacy groups in their dealings with policymakers and provide real-world evidence. Please visit pulseinfoframe.com
rareLife solutions is the rareForward scientific agency built on the insight that rare patients,advocates, and caregivers (PACs) are the primary shapers of their rare disease ecosystem.But we do more than talk about them - we action them, regularly engage them, and integrate them in everything that we do to create a truly collaborative, responsive multi-stakeholder, patient-–driven rare community.We have developed thinking, services, tools, and solutions, including our flagship onevoice.worldcommunity platform, that can help you rareForward too. Please visit rarelifesolutions.com
Synteract is an innovative, full-service contract
research organization supporting
biopharmaceutical companies in all phases of
clinical development to help bring new medicines
to market. Synteract has conducted 4,000+
studies on six continents and in 60+ countries, and
contributed to more than 240 product approvals.
The CRO offers a notable depth of expertise in
rare and orphan diseases, having conducted 130+
clinical trials in the last 5 years alone. In addition,
Synteract focuses in the areas of oncology,
dermatology, pediatric, and neuro degenerative
drug development. Learnmore at
Farmacon is a novel research consulting group ofmedical and logistics experts that specialize inLatin America & Latino populations to getenrollment and market access results incomplicated medical projects, including rare andorphan disease and other medical projects. Ourunique concierge approach includes buildingstrong relationships with key stakeholders, suchas Principal Investigators, Sub-Investigators,referring doctors, KOLs, patient advocacy groups,and families to provide market researchintelligence, access and strategies. Our uniquefeedback mechanism allows sponsors the neededassurance to get the results they seek in apatient-centric world within clinical research andmarket access preparation. Please visit farmacon.co
TREND Community is a digital health company with a mission to improve the quality of life for everyoneliving with rare and chronic disease while accelerating the discovery, development, and delivery of newtreatments. Using artificial intelligence, we capture and quantify the perspectives and lived experiencesof the community from their social data streams. https://trend.community/
David Lapidus founded LapidusData Inc. in 2008 to help orphan drug companies analyze patient populations for rare
diseases where the population dynamics are complex or poorly characterized.
LapidusData brings a commercial perspective to epidemiology and market research
in support of M&A activity, market forecasting, sales, and marketing. Our analyses are used to support the entire
drug development cycle, from pre-clinical planning through commercialization
Early Access Care helps international clientswith effective integrated solutions customizedto their early access needs. Early Access Carespecializes in pre-approval early access,managing the end to end (request intake todelivery at physician) process. Our goal is toMake Access More Accessible™. We offercomprehensive high-touch services to managerequests globally. Please visit earlyaccesscare.com
PerkinElmer Genomics is a state-of-the-art biochemical and molecular genetics laboratory that provides newborn screening and genomic testing services around the world. With over 7.5 million newborns screened since 1994, our laboratory pairs decades of newborn screening experience with a leading-edge clinical genomics program to offer one of the world’s most comprehensive programs for detecting clinically significant genomic changes.